Tags

Type your tag names separated by a space and hit enter

[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12; 43(3):170-172.ZJ

Abstract

The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.

Authors+Show Affiliations

Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.

Pub Type(s)

Journal Article

Language

chi

PubMed ID

32164080

Citation

Li, H, et al. "[Potential Antiviral Therapeutics for 2019 Novel Coronavirus]." Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, vol. 43, no. 3, 2020, pp. 170-172.
Li H, Wang YM, Xu JY, et al. [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):170-172.
Li, H., Wang, Y. M., Xu, J. Y., & Cao, B. (2020). [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, 43(3), 170-172. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.004
Li H, et al. [Potential Antiviral Therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172. PubMed PMID: 32164080.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Potential antiviral therapeutics for 2019 Novel Coronavirus]. AU - Li,H, AU - Wang,Y M, AU - Xu,J Y, AU - Cao,B, PY - 2020/3/13/entrez PY - 2020/3/14/pubmed PY - 2020/3/21/medline KW - 2019 novel coronavirus KW - Antiviral therapy KW - Infection SP - 170 EP - 172 JF - Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases JO - Zhonghua Jie He He Hu Xi Za Zhi VL - 43 IS - 3 N2 - The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials. SN - 1001-0939 UR - https://www.unboundmedicine.com/medline/citation/32164080/[Potential_antiviral_therapeutics_for_2019_Novel_Coronavirus]_ L2 - https://ClinicalTrials.gov/search/term=32164080 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -